Tempus Announces New Strategic Collaboration with Pfizer to Advance Oncology Therapeutic Development

Tempus, a leader in artificial intelligence (AI) and precision medicine, announced a multi-year, strategic collaboration with Pfizer in which the two companies are working together to further AI and machine learning-driven efforts in therapeutic development. The goal of this collaboration is to more precisely gather insights that will inform novel drug discovery and development in oncology.

AiThority Interview : AiThority Interview with João Graça, Co-founder and CTO at Unbabel

“This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”

Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology. Pfizer also has access to Tempus’ broad range of capabilities that support therapeutic R&D, to advance its own oncology portfolio, including AI-driven companion diagnostic offerings and Tempus’ clinical trial matching program, TIME, that rapidly activates studies for patients in communities across the country.

Read More Interview: AiThority Interview with Anthony Katsur, Chief Executive Officer at IAB Tech Lab

“Pfizer shares our commitment to bringing novel treatments to patients faster, and we look forward to working together to usher in the next generation of oncology therapeutics,” said Eric Lefkofsky, Founder and CEO of Tempus. “This is the third strategic collaboration Tempus has established with a global pharmaceutical leader in the last year, as we believe that combining our technological capabilities with pharma’s deep R&D expertise will get us much closer in realizing the full potential of precision medicine.”

 Latest Interview Insights : AiThority Interview with Ritu Bhargava, Chief Product Officer at SAP CX

 [To share your insights with us, please write to sghosh@martechseries.com]